mNP hyperthermia and hypofractionated radiation activate similar immunogenetic and cytotoxic pathways

References

• World Health Organization. WHO | Cancer Factsheet. WHO 2018. doi:/entity/mediacentre/factsheets/fs297/en/index.html
   Google Scholar
• Kumar CSSR, Mohammad F. Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. Adv Drug Deliv Rev. 2011;63(9):789–808.
   PubMed Web of Science ®Google Scholar
• Grüll H, Langereis S. Hyperthermia-triggered drug delivery from temperature-sensitive liposomes using MRI-guided high intensity focused ultrasound. J Control Release. 2012;161(2):317–327.
   PubMed Web of Science ®Google Scholar
• Kraybill WG, et al. A phase I study of fever-range whole body hyperthermia (FR-WBH) in patients with advanced solid tumours: Correlation with mouse models. Int J Hyperth. 2002;18(3):253–266.
   PubMed Web of Science ®Google Scholar
• Hobohm U. Fever and cancer in perspective. Cancer Immunol Immunother. 2001;50(8):391–396.
   PubMed Web of Science ®Google Scholar
• Hergt R, Dutz S, Müller R, et al. Magnetic particle hyperthermia: nanoparticle magnetism and materials development for cancer therapy. J Phys Condens Matter. 2006;18:S2919–S2934.
   Web of Science ®Google Scholar
• Burd R, Dziedzic TS, Xu Y, et al. Tumor cell apoptosis, lymphocyte recruitment and tumor vascular changes are induced by low temperature, long duration (fever-like) whole body hyperthermia. J Cell Physiol. 1998;177:137–147.
   PubMed Web of Science ®Google Scholar
• Mornet S, Vasseur S, Grasset F, et al. Magnetic nanoparticle design for medical diagnosis and therapy. J Mater Chem. 2004;14(14):2161.
   Web of Science ®Google Scholar
• Dewhirst MW, Viglianti BL, Lora-Michiels M, et al. Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. Int J Hyperthermia. 2003;19(3):267–294.
   PubMed Web of Science ®Google Scholar
• Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol. Biol Phys. 1984;10(6):787–800.
   PubMed Web of Science ®Google Scholar
• Toraya-Brown S, Sheen MR, Zhang P, et al. Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors. Nanomedicine. 2014;10(6):1273–1285.
   PubMed Web of Science ®Google Scholar
• Gandhi SJ, Minn AJ, Vonderheide RH, et al. Awakening the immune system with radiation: optimal dose and fractionation. Cancer Lett. 2015;368(2):185–190.
   PubMed Web of Science ®Google Scholar
• Kumari A, Simon SS, Moody TD, et al. Immunomodulatory effects of radiation: what is next for cancer therapy? Future Oncol. 2016;12(2):239–256.
   PubMed Web of Science ®Google Scholar
• Dewhirst M, Viglianti BL, Lora-Michiels M, et al. Thermal dose requirement for tissue effect: experimental and clinical findings. Proc SPIE Int Soc Opt Eng. 2003;4954:37II.
   Google Scholar
• Ko EC, Forsythe K, Buckstein M, et al. Radiobiological rationale and clinical implications of hypofractionated radiation therapy. Cancer Radiotherapie. 2011;15(3):221–229.
   PubMed Web of Science ®Google Scholar
• Whelan TJ, Pignol J-P, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–520.
   PubMed Web of Science ®Google Scholar
• Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: An effective therapy for recurrent high-grade gliomas. J Clin Oncol. 2010;28(18):3048–3053.
   PubMed Web of Science ®Google Scholar
• Formenti SC. Optimizing dose per fraction: a new chapter in the story of the abscopal effect? Int J Radiat Oncol Biol Phys. 2017;99(3):677–679.
   PubMed Web of Science ®Google Scholar
• Popp I, Grosu AL, Niedermann G, et al. Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. Radiother Oncol. 2016;120(2):185–194.
   PubMed Web of Science ®Google Scholar
• Ko EC, Benjamin KT, Formenti SC. Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation. Adv Radiat Oncol. 2018;3(4):486–493.
   PubMedGoogle Scholar
• Schaue D, Ratikan JA, Iwamoto KS, et al. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys. 2012;83(4):1306–1310.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2012;82(5):1744–1748.
   PubMed Web of Science ®Google Scholar
• Johannsen M, Gneveckow U, Eckelt L, et al. Clinical hyperthermia of prostate cancer using magnetic nanoparticles: Presentation of a new interstitial technique. Int J Hyperthermia. 2005;21(7):637–647.
   PubMed Web of Science ®Google Scholar
• Maier-Hauff K, et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol. 2007;81(1):53–60.
   PubMed Web of Science ®Google Scholar
• Johannsen M, et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. Int J Hyperth. 2007;23(3):315–323.
   PubMed Web of Science ®Google Scholar
• Bezman NA, et al. Molecular definition of the identity and activation of natural killer cells. Nat Immunol. 2012;13(10):1000–1009.
   PubMed Web of Science ®Google Scholar
• Vyas JM, Van Der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat Rev Immunol. 2008;8(8):607–618.
   PubMed Web of Science ®Google Scholar
• Dong C, Juedes AE, Temann U-A, et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 2001;409(6816):97–101.
   PubMed Web of Science ®Google Scholar
• Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516.
   PubMed Web of Science ®Google Scholar
• Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9(5):495–502.
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(7):542–542.
   Web of Science ®Google Scholar
• Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 2007;7(6):454–465.
   PubMed Web of Science ®Google Scholar
• Pardo J, Bosque A, Brehm R, et al. Apoptotic pathways are selectively activated by granzyme A and/or granzyme B in CTL-mediated target cell lysis. J Cell Biol. 2004;167(3):457–468.
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499–511.
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol. 2007;7(3):179–190.
   PubMed Web of Science ®Google Scholar
• Makrilia N, Kollias A, Manolopoulos L, et al. Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest. 2009;27(10):1023–1037.
   PubMed Web of Science ®Google Scholar
• Chalkley HW. Method for the quantitative morphologic analysis of tissues. J Natl Cancer Inst. 1943;4:47–53.
   Google Scholar
• Demidenko E. Three endpoints of in vivo tumour radiobiology and their statistical estimation. Int J Radiat Biol . 2010;86(2):164–173.
   PubMed Web of Science ®Google Scholar
• Demidenko E. Mixed models: theory and applications with R. 2nd edn. New Jersey (NJ): John Wiley & Sons, Inc.; 2013.
   Google Scholar
• Glasner A, et al. Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. J Immunol. 2012;188(6):2509–2515.
   PubMed Web of Science ®Google Scholar